AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 22, 2021- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1]
-
February 19, 2021
-
February 18, 2021
-
February 10, 2021- Collaboration leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders
-
February 10, 2021-- Children living with neurogenic detrusor overactivity who are not adequately managed with anticholinergic medication now have a new treatment option prior to surgical intervention
-
February 03, 2021- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
-
January 26, 2021NEW TECHNOLOGY ALLOWS FOR THE TREATMENT OF TWO AREAS OF FAT AT ONCE AND NEW ELITE APPLICATORS DESIGNED FOR IMPROVED FIT AND COMFORT
-
January 25, 2021- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
-
January 15, 2021- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
-
January 12, 2021-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts --
-
January 07, 2021- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo[1,2]
-
January 05, 2021- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001)[1]
-
December 23, 2020- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM
-
December 11, 2020- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4]
-
December 10, 2020- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
-
December 09, 2020- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis[1]
-
December 05, 2020- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab compared to 17.0 months in patients taking bendamustine plus rituximab (BR) after three years or more off treatment[1]
-
December 02, 2020- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
-
December 01, 2020
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
